

# Stefano Cavalieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7800713/publications.pdf>

Version: 2024-02-01

75  
papers

882  
citations

430874

18  
h-index

552781

26  
g-index

77  
all docs

77  
docs citations

77  
times ranked

1348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. <i>Oral Oncology</i> , 2022, 126, 105756.	1.5	1
2	Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9520-9520.	1.6	5
3	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. <i>Tumori</i> , 2021, 107, 030089162095284.	1.1	4
4	Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 771-779.	1.6	3
5	AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 357-372.	4.4	7
6	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide <scp>EU</scp> Project. <i>Head and Neck</i> , 2021, 43, 601-612.	2.0	18
7	Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. <i>Tumori</i> , 2021, , 030089162110079.	1.1	0
8	Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. <i>Endocrine</i> , 2021, 73, 641-647.	2.3	10
9	Next generation platinum salt in nasopharyngeal carcinoma. <i>Lancet Oncology, The</i> , 2021, 22, 577-578.	10.7	1
10	Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6077-6077.	1.6	0
11	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. <i>International Journal of Cancer</i> , 2021, 149, 675-683.	5.1	11
12	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	2.0	12
13	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. <i>Cancers</i> , 2021, 13, 3271.	3.7	12
14	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of Aqualief™ Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. <i>Cancers</i> , 2021, 13, 3456.	3.7	3
15	Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. <i>Cancers</i> , 2021, 13, 3983.	3.7	1
16	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1526-1527.	3.0	1
17	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4061-4068.	1.6	24
18	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. <i>Radiotherapy and Oncology</i> , 2021, 164, 1-5.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Particle Beam Therapy Tolerance and Outcome on Patients with Autoimmune Diseases: A Single Institution Matched Caseâ€“Control Study. <i>Cancers</i> , 2021, 13, 5183.	3.7	1
20	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirusâ€“Positive Oropharyngeal Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1666-1676.	3.0	6
21	Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review. <i>Frontiers in Oncology</i> , 2021, 11, 789079.	2.8	11
22	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, .	0.8	3
23	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020, 130, 857-865.	2.0	25
24	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 518110.	2.8	9
25	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020, 12, 2958.	3.7	29
26	Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients. , 2020, 2020, 1152-1155.		3
27	Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. <i>Cancers</i> , 2020, 12, 3769.	3.7	2
28	Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma. <i>Cancer</i> , 2020, 126, 3624-3626.	4.1	2
29	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020, 136, 35-42.	2.8	27
30	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020, 126, 1888-1894.	4.1	54
31	Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). <i>Oral Oncology</i> , 2020, 108, 104766.	1.5	5
32	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. <i>PLoS ONE</i> , 2020, 15, e0232639.	2.5	35
33	Title is missing!. , 2020, 15, e0232639.		0
34	Title is missing!. , 2020, 15, e0232639.		0
35	Title is missing!. , 2020, 15, e0232639.		0
36	Title is missing!. , 2020, 15, e0232639.		0

#	ARTICLE	IF	CITATIONS
37	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1057.	3.7	25
38	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019, 41, 3670-3676.	2.0	29
39	Quality Assessment in Supportive Care in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 926.	2.8	8
40	PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. <i>Oncology</i> , 2019, 97, 112-118.	1.9	1
41	Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. <i>European Journal of Cancer</i> , 2019, 115, 4-12.	2.8	18
42	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	1.2	9
43	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 435-443.	4.1	8
44	Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. <i>Breast Journal</i> , 2019, 25, 237-242.	1.0	1
45	Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. <i>Oncology Research and Treatment</i> , 2019, 42, 182-189.	1.2	22
46	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. <i>European Journal of Cancer</i> , 2019, 110, 62-70.	2.8	46
47	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.7	16
48	Integrating population data in a computerized Decision Support System for Head and Neck Cancer. , 2019, , .		0
49	Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz102.	0.4	3
50	Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6029-6029.	1.6	2
51	Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17530-e17530.	1.6	3
52	Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. <i>Drugs in Context</i> , 2019, 8, 1-6.	2.2	7
53	Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17537-e17537.	1.6	0
54	Lenvatinib-induced renal failure: two first-time case reports and review of literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 379-385.	3.3	27

#	ARTICLE	IF	CITATIONS
55	Immunotherapy for recurrent/metastatic head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 152-156.	1.8	28
56	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018, 104, 213-220.	1.1	4
57	Clinical implications for pro-GRP in small cell lung cancer. A single center experience. <i>International Journal of Biological Markers</i> , 2018, 33, 55-61.	1.8	18
58	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018, 65, 78-86.	7.7	32
59	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. <i>European Journal of Cancer</i> , 2018, 97, 7-15.	2.8	34
60	Fatigue, a major still underestimated issue. <i>Current Opinion in Oncology</i> , 2018, 30, 219-225.	2.4	23
61	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6086-6086.	1.6	7
62	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	1.8	73
63	Druggable molecular targets in skin adnexal malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21619-e21619.	1.6	0
64	Concurrent chemoradiation for non-metastatic anal carcinoma: A case series from a single institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15575-e15575.	1.6	0
65	Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 349-361.	4.7	65
66	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. <i>Breast Care</i> , 2017, 12, 391-394.	1.4	9
67	Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC). <i>Annals of Oncology</i> , 2017, 28, vi34.	1.2	1
68	Uncommon Somatic Mutations in Metastatic NUT Midline Carcinoma. <i>Tumori</i> , 2017, 103, S5-S8.	1.1	10
69	Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single institution experience. <i>Annals of Oncology</i> , 2017, 28, vi68.	1.2	0
70	A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, vi68.	1.2	0
71	A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer. <i>Annals of Oncology</i> , 2017, 28, vi74.	1.2	0
72	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9543-9543.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XD06-XD08.	0.8	3
74	Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response (LTR) to vemurafenib (Vb).. Journal of Clinical Oncology, 2017, 35, e21001-e21001.	1.6	0
75	Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience. Tumori, 2016, 102, 501-507.	1.1	6